United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Technology Industry News Inside Advent’s $2.5bn bet on Sapiens and the next wave of AI-powered insurance tech Sapiens to be acquired by Advent for $2.5B at a 64% premium. Discover how going private could accelerate its AI-driven insurance software strategy. byPallavi MadhirajuAugust 13, 2025